Related by context. All words. (Click for frequent words.) 76 Aflibercept 75 non nucleoside inhibitor 75 Romidepsin 75 CYT# potent vascular disrupting 75 relapsed MM 75 Gleevec resistant 75 Phase 2b Clinical Trial 74 antibody MAb 74 refractory chronic lymphocytic 74 dasatinib Sprycel 74 oral prodrug 74 Xanafide 74 vinca alkaloid 74 orally administered inhibitor 74 sodium glucose cotransporter 74 evaluating tivozanib 74 triggers apoptosis programmed 74 PNP inhibitor 74 Cloretazine 74 PKC# 74 Annamycin 74 Sapacitabine 74 novel VDA molecule 74 Ceflatonin R 73 demonstrated antitumor activity 73 receptor tyrosine kinase inhibitor 73 relapsed multiple myeloma 73 Meets Primary Endpoint 73 Cloretazine ® 73 liposomal formulation 73 Hsp# Inhibitor 73 lenalidomide Revlimid R 73 gefitinib Iressa 73 Deforolimus 73 Initiates Enrollment 73 LymphoStat B belimumab 73 Enzastaurin 73 MAGE A3 ASCI 73 acyclovir Lauriad R 73 Maribavir 73 Nitazoxanide 73 IMiDs ® 73 AAG geldanamycin analog 73 Phase Ib II 72 PSMA ADC 72 nucleotide analog 72 histone deacetylase HDAC inhibitor 72 Elotuzumab 72 GMX# 72 erlotinib Tarceva ® 72 fosbretabulin 72 SPRYCEL ® 72 dasatinib Sprycel ® 72 Panzem R NCD 72 Combination REOLYSIN R 72 MTP inhibitor 72 AEG# 72 PRTX 72 PEGylated Fab fragment 72 Sudhir Agrawal D.Phil 72 Panzem R 72 Alfacell proprietary ribonuclease 72 Antiangiogenic 72 Pivotal Phase III 72 Initiate Phase 72 IL# PE#QQR 72 GRN# 72 Phase 2b Study 72 Myelodysplastic Syndrome MDS 72 cell lymphoma CTCL 72 Cutaneous T 72 Clolar ® 72 Epratuzumab 72 YONDELIS 72 ara C 72 leukemia AML 72 Blinatumomab 72 nucleoside analog 72 oxidative stress inducer 72 alfa 2a 72 Aurora Kinase 72 Onconase 72 Talabostat 72 AEGR 72 HGS ETR2 71 Bosutinib 71 intranasal formulation 71 thalidomide Thalomid 71 MEK inhibitor 71 HGS ETR1 71 imatinib Gleevec ® 71 proteasome inhibitor 71 FOLOTYN ® 71 INCB# [001] 71 sunitinib Sutent ® 71 Bezielle 71 Personalized Immunotherapy 71 Quinamed 71 HGS ETR1 mapatumumab 71 Nilotinib 71 targeted radiotherapeutic 71 Cloretazine R 71 Phase #b/#a clinical 71 IMiDs R 71 kidney urologic 71 Pathway Inhibitor 71 Phase IIb Trial 71 Temsirolimus 71 PSN# [001] 71 Elesclomol 71 GW# [003] 71 LymphoStat B TM 71 investigational monoclonal antibody 71 selective kinase inhibitor 71 lumiliximab 71 Cethromycin 71 Dacogen decitabine 71 Polymerase Inhibitor 71 pan HDAC inhibitor 71 docetaxel Taxotere R 71 alpha folate receptor 71 MKC# MT 71 Prolongs Survival 71 GVAX ® 71 midstage clinical 71 pharmacokinetic PK study 71 Tezampanel 71 Darinaparsin 71 Bayer HealthCare Onyx Pharmaceuticals 71 Pivotal Phase 71 pathophysiological effects 71 Voreloxin 71 Janus kinase 71 Chronic Myeloid Leukemia 71 Archexin 71 Tesetaxel 71 Albuferon TM 71 TRAIL R2 71 PI3K/Akt pathway inhibitor 71 humanized anti 71 estramustine 71 Glufosfamide 71 Vidaza azacitidine 71 KRN# 71 investigational oral hepatitis C 71 Antitumor Activity 71 FOLFOX6 chemotherapy regimen 71 Safinamide 71 Pralatrexate 71 Pemetrexed 71 selective modulator 71 Virulizin ® 71 Vidaza ® 71 Initiates Phase II 71 HGS# 71 Phase IIb Clinical Trial 71 virus HCV protease inhibitor 71 Dasatinib 71 Completes Patient Enrollment 71 histone deacetylase inhibitor 71 therapeutic monoclonal antibody 71 AKT inhibitor 71 2 methoxyestradiol 71 Diffuse Large B 71 Daclizumab 71 galiximab 71 metaglidasen 71 Phase 2b Trial 71 cutaneous T 71 mertansine 71 visilizumab 71 targeting CD# 71 OMP #M# 70 docetaxel Taxotere ® 70 Silodosin 70 Ozarelix 70 Golimumab 70 humanised monoclonal antibody 70 JAK inhibitor 70 CIMZIA TM 70 Begins Dosing 70 Nexavar ® 70 investigational humanized monoclonal antibody 70 Severe Sepsis 70 oral picoplatin 70 PEG IFN 70 bortezomib Velcade R 70 novel tubulin binding 70 chimeric monoclonal antibody 70 CTAP# Capsules 70 Tarceva TM 70 hypereosinophilic syndrome 70 PEG SN# 70 mapatumumab 70 lintuzumab SGN 70 pomalidomide 70 agonistic human 70 Hormone Refractory Prostate Cancer 70 accumulate preferentially 70 Mipomersen 70 Randomized Phase 70 Seliciclib 70 adalimumab Humira 70 Achieves Primary Endpoint 70 telomerase therapeutic 70 Anti Tumor 70 Tyrosine Kinase Inhibitor 70 bortezomib Velcade 70 ganetespib 70 Clofarabine 70 huC# DM4 70 ENMD # 70 metastatic malignant 70 phase IIb clinical 70 Degarelix 70 targeted antifolate 70 long acting muscarinic 70 ALN TTR 70 oral antiviral 70 PDX pralatrexate 70 cetuximab Erbitux R 70 Initiates Clinical Trial 70 YONDELIS R 70 forodesine 70 oral Janus kinase 70 Perifosine 70 HQK 70 Elvitegravir 70 leukemia CLL 70 cilengitide 70 multicenter Phase II 70 oral proteasome inhibitor 70 Alocrest 70 Muraglitazar 70 Factor VIIa 70 Carfilzomib 70 Pegloticase 70 sorafenib tablets 70 beta 1a 70 OMP #R# 70 alvespimycin 70 depsipeptide 70 VNP#M 70 MKC# MKC# PP 70 Kinase Inhibitor 70 Copegus ribavirin 70 CBLC# 70 phase Ib 70 Initiates Clinical 70 uricase 70 Teriflunomide 70 Elagolix 70 Vaccine Adjuvant 70 R lenalidomide 70 Immunotherapeutic 70 Crizotinib 70 Irinotecan 70 huN# DM1 70 Pazopanib 70 dexamethasone Decadron 70 EGFR HER2 70 Omacetaxine mepesuccinate 70 sorafenib Nexavar 70 Anti VEGF 70 Ceflatonin 70 sorafenib Nexavar ® 69 ® lenalidomide 69 Tyrima 69 bendamustine 69 cisplatin gemcitabine 69 CDK inhibitor 69 OvaRex R 69 small molecule tyrosine 69 ceftazidime 69 novel topoisomerase 69 CG# [003] 69 Pertuzumab 69 Cytotoxic 69 Zalypsis 69 ISTODAX ® 69 Lenocta 69 Vidaza R 69 Squalamine 69 Kahalalide F 69 novel peptide 69 BAY #-# 69 class anticancer quinolone 69 peptidic compound 69 T#I [002] 69 Refractory Hodgkin Lymphoma 69 refractory cutaneous T 69 small molecule Hedgehog 69 alefacept 69 IAP inhibitor 69 Aliskiren 69 Panzem NCD 69 Amrubicin 69 Denufosol 69 novel immunomodulatory 69 protein tyrosine phosphatase 1B 69 PRT# 69 vinorelbine tartrate 69 R#/MEM # 69 Ridaforolimus 69 brivanib 69 NS#/#A protease 69 Vicriviroc 69 mTOR mammalian target 69 systemic anaplastic large 69 TNF alpha selectively neutralizing 69 Phase Ib IIa 69 Fabry Disease 69 Aplidin 69 OncoVex 69 Oral Fingolimod 69 RAV# 69 JAK2 inhibitor 69 Phase Ib study 69 Triapine 69 essential thrombocythemia ET 69 IMiDs ® compound 69 IgG1 monoclonal antibody 69 Tumor Necrosis Factor 69 Preclinical Study 69 novel histone deacetylase 69 OXi# 69 Relapsed Refractory 69 Presents Preclinical Data 69 Initiates Phase III 69 Curaxin CBLC# 69 relapsed leukemia 69 Janus Kinase 69 Darusentan 69 rxRNA 69 Monoclonal Antibody 69 Bortezomib 69 BRIM2 69 Dapagliflozin 69 relapsed refractory multiple myeloma 69 acadesine 69 deforolimus 69 Hedgehog Pathway Inhibitor 69 Initiate Clinical Trial 69 HDAC Inhibitor 69 SinuNase ™ 69 AFREZZA TM 69 Xeloda ® 69 CEQ# 69 recurrent glioblastoma multiforme 69 generation purine nucleoside 69 Fludara ® 69 systemic RNAi therapeutic 69 trastuzumab Herceptin R 69 Investigational Compound 69 Phase Ib clinical 69 idiopathic thrombocytopenic purpura ITP 69 IMC A# 69 rALLy clinical trial 69 Pharmacokinetics PK 69 Investigational Treatment 69 Symadex 69 Naive Patients 69 MGd 69 Vicinium TM 69 ON #.Na 69 hyaluronidase enzyme 69 paclitaxel Taxol ® 69 Tipranavir 69 ® bortezomib 69 vascular disrupting agent 69 refractory NSCLC 69 orally bioavailable 69 initiated Phase Ib 69 mGluR5 negative 69 apoptosis inducer 69 Velcade bortezomib 69 Peginterferon alfa 2b 69 Phase 2a Clinical Trial 69 PD LID 69 NXL# 69 Phase 2a Trial 69 q8h 69 OHR/AVR# 69 Cotara ® 69 BARACLUDE ® 69 Saxagliptin 69 TRO# 69 thetreatment 69 DEB# 69 KNS # 69 polymerase inhibitor 69 imatinib Gleevec 69 ALN HPN 69 Evoltra ® 68 sitaxsentan 68 immunotherapeutic agent 68 gamma secretase inhibitor 68 Leukemias 68 potent antiproliferative 68 5 FU leucovorin 68 monoclonal antibody conjugated 68 radezolid 68 Bendamustine 68 Factor Receptor 68 idiopathic thrombocytopenic purpura 68 ALN PCS 68 cetuximab Erbitux ® 68 CLORETAZINE TM VNP#M 68 Gemzar ® 68 epigenetic therapies 68 R sorafenib tablets 68 treatment naïve genotype 68 Complicated Skin 68 Azacitidine 68 pralatrexate injection folate analogue 68 IAP inhibitors 68 CCR5 mAb 68 pediatric acute lymphoblastic 68 Traficet EN 68 inhalation powder 68 Presents Positive Preclinical 68 Decitabine 68 Presents Positive 68 soluble tumor necrosis 68 elotuzumab 68 immunotoxin 68 TELINTRA 68 HuLuc# 68 Pulmonary Arterial Hypertension 68 CA4P 68 TO AVOID PREGNANCY WHILE 68 XL# anticancer compounds 68 Iloperidone 68 delta opioid receptor 68 nucleoside analogue 68 rituximab Rituxan 68 Laquinimod 68 OncoVEX GM CSF 68 hyperphenylalaninemia HPA due 68 TTF Therapy 68 Successfully Completes Phase 68 VEGFR2 inhibitor 68 humanized monoclonal 68 ribavirin RBV 68 hypoxia inducible factor 68 peripherally acting 68 highly selective inhibitor 68 Monoclonal antibody 68 investigational HCV polymerase 68 Receives Orphan Drug Designation 68 Alemtuzumab 68 Cytarabine 68 brand ciclesonide HFA 68 RNAi Therapeutic 68 Plicera 68 AVONEX ® 68 anti secretory 68 Alinia 68 SAR# [004] 68 PEGylated anti 68 Enzyme Replacement Therapy 68 HCV SPRINT 68 pertuzumab 68 Vidofludimus 68 IMC #B 68 Orally administered 68 Novel Oral 68 Investigational Oral 68 Antigen Specific 68 velafermin 68 CD# monoclonal antibody 68 Pimavanserin 68 Drug Candidate 68 bevacizumab Avastin ® 68 Mg Usa 68 Corlux 68 SinuNase TM 68 ALGRX 68 oral renin inhibitor 68 MNTX 68 HCD# [002] 68 OMNARIS HFA 68 Neulasta ® 68 polyglutamate 68 DermaVir Patch 68 Granulocyte Colony Stimulating Factor 68 EZN 68 somatostatin analog 68 Initiated Phase 68 TKB# 68 topically administered 68 Xelox 68 gemcitabine carboplatin 68 administered subcutaneously 68 IMPDH inhibitor 68 tubulin inhibitor 68 recurrent glioblastoma multiforme GBM 68 Phase IIb clinical trials 68 cMET 68 investigational protease inhibitor 68 indolent follicular non 68 Idiopathic Pulmonary Fibrosis 68 refractory indolent non 68 Tolvaptan 68 pegylated interferon alpha 68 tumor xenograft models 68 papillary renal cell carcinoma 68 HuMax EGFr 68 Allovectin 7 R 68 acetonide FA 68 treatment naive genotype 68 cortisol synthesis 68 investigational immunotherapy 68 Pivotal Study 68 Pegylated Interferon 68 Dose Ranging Study 68 potent topoisomerase II 68 Exelixis XL# 68 immune modulatory 68 xenograft models 68 hypoxia activated prodrug 68 Luteinizing Hormone Releasing Hormone 68 alkylating agent 68 Bavituximab 68 DPP4 inhibitor 68 HSP# inhibitor 68 thiazolides 68 MT#/MEDI-# 68 PDE4 inhibitor 68 antimetabolite 68 Metastatic Melanoma 68 RNAi therapeutic targeting 68 induced macular edema 68 vemurafenib 68 HCV RNA polymerase 68 Eculizumab 68 Inhalation Solution 68 Phase III Pivotal 68 Alferon N 68 Kamada AAT 68 VAPRISOL 68 OncoVEX 68 plus prednisone prednisolone 68 Tesmilifene 68 CYP#A# CYP#D# 68 Epidermal Growth Factor Receptor 68 Rindopepimut 68 non nucleoside HCV 68 Leukine ® 68 ZOLINZA 68 tyrosine kinase inhibitor TKI 68 Study Evaluating 68 gastrin analogue TT 68 talabostat 68 Glioblastoma Multiforme 68 vorinostat 68 Advanced Renal Cell 68 Virologic 68 developing Bicifadine serotonin 68 Advanced Melanoma 68 ATRA IV 68 vidofludimus 68 Phase 1b trial 68 paclitaxel poliglumex 68 echinocandin 68 Vascular Disrupting Agent 68 Kinase Inhibitors 68 Proxinium TM 68 Pegylated 68 sunitinib malate 68 Cannabinor 68 Zybrestat 68 reslizumab 68 Acute Myeloid Leukemia AML 68 romidepsin 68 VitiGam 68 signal transduction inhibitor 68 Panzem 68 Pharmacokinetic Study 68 blinded randomized placebo controlled 68 radiation sensitizer 68 JAK1 68 ISTODAX 68 TACI Ig 68 metastatic colorectal 68 Campath ® 68 Phase #/#a trial 68 ospemifene 68 oral ghrelin agonist 68 CCR9 antagonist 68 TNF Tumor Necrosis Factor 68 Campath alemtuzumab 68 topoisomerase II inhibitor 68 BioNumerik 68 Bafetinib 68 lomitapide 68 Civacir 68 Orally Active 68 ARRY # 68 5 HT2A inverse 68 II Clinical Trial 68 Talactoferrin 68 Pegasys ® 68 Clinical Trial Results 68 Methylnaltrexone 68 phase IIb trial 67 HCV protease 67 protein kinase inhibitor 67 pentostatin 67 Ambrisentan 67 advanced metastatic renal 67 plus DOXIL 67 Preclinical Models 67 Systemic Delivery 67 methylnaltrexone bromide 67 Interferon alpha 67 Lupus Nephritis 67 Aclidinium 67 trial evaluating PRX# 67 Thiarabine 67 Cyclooxygenase Inhibiting Nitric Oxide 67 Thiovir 67 preclinical efficacy 67 Imatinib mesylate 67 Xcytrin R 67 pegylated interferon alfa 2a 67 NS5B polymerase 67 TRACON Pharmaceuticals 67 rhIGF-I/rhIGFBP-3 67 oral rivaroxaban 67 Diabetic Nephropathy 67 tumor vascular disrupting 67 atypical Hemolytic Uremic Syndrome 67 Oral Calcitonin 67 seliciclib CYC# 67 Cell Lymphoma 67 TRV# [001] 67 Bucindolol 67 eniluracil 67 NS5b 67 renin inhibitor 67 P#X# antagonist 67 FUSILEV enhances 67 sorafenib Nexavar R 67 ixabepilone 67 RhuDex ® 67 EVIZON TM 67 decitabine 67 Interferon alfa 67 orally inhaled migraine 67 molecular imaging radiopharmaceutical 67 novel nucleoside analog 67 PEGylated interferon 67 Azedra 67 Protein Kinase C 67 NPC 1C 67 Liprotamase 67 steroid refractory GvHD 67 pan histone deacetylase 67 TTR amyloidosis 67 small molecule chemotherapeutic 67 Phase 1b clinical trials 67 Valopicitabine 67 TLK# 67 CRLX# 67 EXPAREL TM 67 Phase 1a clinical 67 selective antagonist 67 Tasimelteon 67 Ganciclovir 67 Angiotensin Converting Enzyme 67 Teplizumab 67 tyrosine kinase inhibitor 67 multi kinase inhibitor 67 Ribavirin causes 67 Anidulafungin 67 compound INCB# 67 Parathyroid Hormone 67 hormone refractory metastatic prostate 67 ritonavir boosted 67 Pafuramidine 67 Genz # 67 leukemia ALL 67 selective adenosine 67 5 fluorouracil leucovorin 67 bendamustine ifosfamide 67 Tarvacin TM 67 reversible inhibitor 67 MGCD# [001] 67 UPLYSO 67 oncolytic 67 Chemophase 67 Preclinical Data 67 Dalbavancin 67 Myelofibrosis 67 ADP receptor antagonist 67 mda 7 67 PF # [002] 67 5 HT6 receptor 67 ORENCIA R 67 selective orally bioavailable 67 phase IIa clinical 67 favorable pharmacokinetic profile 67 IMA# 67 Files IND 67 Onyx Pharmaceuticals Announces 67 Fluorouracil 67 Telik logo TELINTRA 67 Melphalan 67 TOCOSOL Camptothecin 67 Demonstrates Potent 67 Trastuzumab DM1 67 Interferon Beta 67 potent suppressor 67 familial amyloidotic polyneuropathy FAP 67 bosutinib 67 TBC# 67 novel emulsion formulation 67 Ocrelizumab 67 Zolinza 67 LEUKINE 67 Brentuximab Vedotin SGN 67 R Saizen R 67 Vivecon 67 platinum chemotherapeutic 67 TLR9 agonist 67 ATL/TV# 67 CD3 monoclonal antibody 67 LAB CGRP 67 topical gel formulation 67 corticosteroid dexamethasone 67 delafloxacin 67 neratinib 67 Triapine R 67 JAK2 Inhibitor 67 Phase III Clinical Trial 67 ACTEMRA TM 67 systemic antifungal 67 nilotinib Tasigna 67 generation Hsp# inhibitor 67 PSN# [002] 67 JVRS 67 p# biomarker 67 HuMax CD# 67 Commence Phase 67 #mg/#mg 67 PEG Interferon lambda 67 small molecule defensin 67 cytokine refractory 67 albiglutide 67 Presents Preclinical 67 baminercept 67 THR beta agonist 67 CCX# B 67 MT# MEDI 67 Therapeutic Competitors Companies 67 maximally tolerated dose 67 Exherin TM 67 xanthine oxidase inhibitor 67 oral ridaforolimus 67 Aptivus ® 67 bevacizumab Avastin R 67 cyclophosphamide methotrexate 67 Perifosine KRX 67 MEK Inhibitor 67 Zorbtive TM 67 Telbivudine 67 Tumour Vascular Disrupting Agent 67 Treatment Naïve 67 PROSTVAC VF 67 Neulasta R 67 EGFR TKI 67 First Patient Dosed 67 Fulvestrant 67 Anti Tumor Activity 67 Immunomodulatory 67 compound perifosine 67 p# inhibitor 67 Phase #b/#a trial 67 alpha 2a 67 nilotinib Tasigna ® 67 Phase IIa Clinical Trial 67 Romiplostim 67 TREANDA 67 OvaRex ® MAb 67 histamine dihydrochloride 67 CYC# 67 G#DT 67 evaluating mipomersen 67 BENLYSTA TM 67 oncolytic virus therapies 67 See CLINICAL PHARMACOLOGY 67 Aeolus Pharmaceuticals Announces 67 oral deforolimus 67 REP# 67 mTOR inhibitor 67 ESBA# 67 Ophena TM 67 Commences Phase 67 GLPG# 67 Fondaparinux 67 Ofatumumab 67 Gefitinib 67 Single Dose 67 Rilonacept 67 Pegylated Liposomal Doxorubicin 67 Epstein Barr Virus EBV 67 MKC# 67 cis retinoic acid 67 MEK inhibitors 67 5 Fluorouracil 67 Hycamtin ® 67 Amgen Neulasta R 67 doxorubicin cyclophosphamide 67 milatuzumab 67 Diabetic Neuropathy 67 Lymphocytic 67 IMiDs 67 Rigel R# 67 Transdermal Patch 67 mGluR5 NAM 67 AMN# [001] 67 cathepsin K inhibitor 67 Phase IIIb clinical 67 Protease Inhibitor 67 Soliris eculizumab 67 CCR5 antagonist 67 endothelin receptor antagonists 67 MabCampath 67 Fodosine 67 Olaparib 67 Trial Evaluating 67 tigecycline 67 GRNVAC1 67 Granted Orphan Drug 67 registrational Phase 67 poly ADP ribose polymerase 67 product candidate Lpathomab 67 dihydrofolate reductase 67 non peptidic protease 67 myelofibrosis polycythemia vera 67 INCB# [003] 67 Inhalation Powder 67 PARI Pharma GmbH 67 Isavuconazole 67 KSP inhibitor 67 Fludarabine 67 mGluR2 NAM 67 follicular Non Hodgkin 67 candidates Azedra TM 67 small molecule glucokinase 67 meropenem 67 Myocet 67 colon carcinoma 67 Troxatyl 67 biliary tract cancer 67 gemcitabine cisplatin 67 Rebif ® 67 Eraxis 67 CIMZIA TM certolizumab pegol 67 dextromethorphan quinidine 67 Aplidin R 67 Peg IFN 67 Chronic Lymphocytic Leukemia CLL 67 Copegus ® 67 Allovectin 7 ® 66 CCX# 66 HuMax CD4 66 adecatumumab MT# 66 myelodysplastic myeloproliferative diseases 66 monoclonal antibody MAb 66 BARACLUDE R 66 Guanilib 66 budesonide foam 66 stated Michelle Berrey 66 metastatic castration resistant 66 Previously Treated 66 acute myeloid 66 SUTENT ® 66 K ras mutations 66 nitazoxanide 66 hour bronchodilation 66 Peginterferon 66 viral kinetics 66 ATL# [001] 66 Cetrorelix 66 aflibercept VEGF Trap 66 leading oral taxane 66 anti CD3 66 CD# CEA 66 TELINTRA R 66 angiogenesis inhibitor 66 ALN TTR# 66 Solazed TM 66 antisense drug 66 vapreotide acetate 66 Anthracycline 66 class mGluR5 inhibitor 66 trastuzumab DM1 T DM1 66 Antiviral Activity 66 Pivotal Trial 66 AQ4N 66 docetaxel chemotherapy 66 Smac mimetics 66 Nanobody 66 anticoagulant reversing agent 66 MCyR 66 somatostatin analogue 66 allosteric modulator NAM 66 volociximab 66 evaluating picoplatin 66 CIMZIA ™ 66 toenail onychomycosis 66 Mycophenolate Mofetil 66 Vandetanib 66 Adenoviral 66 SNT-MC#/idebenone 66 ENESTnd 66 amrubicin 66 Crofelemer 66 oral dihydropyrimidine dehydrogenase DPD 66 Sym# 66 HoFH 66 selective inhibition 66 Quinamed R 66 fluoropyrimidine 66 Valproic acid 66 JAK inhibitors 66 A3 adenosine receptor 66 INSPIRE Trial Phase III 66 Fc fusion protein 66 XL# XL# 66 castrate resistant prostate cancer 66 Randomized Double blind 66 Tarvacin 66 ELACYT 66 gemcitabine Gemzar ® 66 Patients Treated With 66 lintuzumab 66 secretory phospholipase A2 66 immune modulating 66 Nexavar sorafenib 66 rilonacept 66 Oral Mucositis 66 replicon 66 HCV polymerase 66 Liposomal 66 atypical hemolytic uremic syndrome 66 irinotecan doxorubicin oxaliplatin paclitaxel 66 busulfan 66 proprietary polysaccharide 66 Vitaxin 66 Recombinant Human 66 NDA Submission 66 vascular disrupting agents 66 nucleotide analogue 66 Chronic lymphocytic leukemia 66 SAR# [002] 66 achieved CCyR 66 lexidronam injection 66 Lisofylline LSF 66 JAK2 V#F 66 XYOTAX TM 66 receptor monoclonal antibody 66 TLR7 agonist 66 Phase III Clinical Trials 66 tenofovir disoproxil fumarate Viread 66 Genentech Rituxan 66 Shows Promise Against 66 daptomycin 66 Nasdaq HALO 66 Phase III Trial 66 Genasense ® oblimersen 66 apomorphine hydrochloride 66 Icatibant 66 diarrhea predominant irritable 66 Vion Pharmaceuticals 66 acute leukemias 66 oral JAK#/JAK# inhibitor 66 Malignant Melanoma 66 including eniluracil ADH 66 doripenem 66 Vitro Activity 66 trodusquemine 66 PHX# 66 multitargeted 66 acute GvHD 66 davunetide intranasal AL 66 Amgen Neulasta ® 66 herpetic keratitis 66 cardio renal 66 Vascugel 66 Dyloject TM 66 RELOVAIR ™ 66 Initiates Phase 66 isoform selective 66 metastatic malignant melanoma 66 Chronic Hepatitis C 66 omacetaxine mepesuccinate